Search
Confirm
Cancel
NEWS
News
>
News
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
ProfoundBio
SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics
Learn More +
SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
ProfoundBio
WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China.
Learn More +
WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China.
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
ProfoundBio
Previous page
1
2

Contact us

Address:Suite 101&102, Bldg 1, P3A, 1 Xinze Street, SIP, Suzhou, China
E-mail:info@profoundbio.com

Copyright © 2021 ProfoundBio (Suzhou) Co., Ltd.   All rights reserved. 苏ICP备2021002620号 Powered by www.300.cn